Melatonin in Oncology - Study Notes

Study-note hub covering melatonin's mitochondrial, immune, phase-separation, fibrotic, and dosing questions in oncology research

This hub brings the melatonin oncology pages into one structure.

Use it as a map.

The pages here are part of one hub, but they cover different evidence tiers and different use cases.

What this hub is trying to separate

Melatonin sits in three linked but distinct oncology conversations.

• Moderate evening oral use as a circadian and immune-support adjunct
• Very high pharmacological exposure as a possible mitochondrial stress strategy
• Phase-separation and fibrosis biology as a newer mechanistic framework

Those conversations overlap.

They are not interchangeable.

Start here

Pick the track that matches the question you are trying to answer.

Track 1 — Human adjunct use

Start here when the question is about real-world oral use, immune tone, timing, or the better-supported clinical literature.

• Moderate-Dose Immune Effects and Timing — the main human adjunct page, including the Lissoni-style context and the usual 20 to 40 mg nightly discussion
• Addendum — Dosing, Th1/Th2, and Recalibration — why continuous high-dose daily use can work against the immune goal, and how to think about resetting the strategy

Track 2 — High-dose mitochondrial model

Start here when the question is about RET, ROS, tumour-selective stress, or the difference between swallowed dose and systemic exposure.

• High-Dose Mitochondria, RET, and ROS — the mechanistic page on reverse electron transport, ROS burst, uncoupling, and apoptosis
• Dosing, Bioavailability, and Human Scaling — how mouse and cell work translate into rough human exposure estimates, and where that translation remains uncertain

Track 3 — Condensates, fibrosis, and stress adaptation

Start here when the question is about YAP/TAZ, oncogenic condensates, stromal biology, or why melatonin is being linked to deeper stress-adaptation models.

• Phase Separation in Oncology — the main condensate framework, including the three axes and the proposed melatonin levers
• Fibrotic Drivers and the 26-Gene Signature — how the condensate discussion overlaps with EMT, fibrosis, CAF biology, and stromal remodelling

Additional hub pages

These pages support the main tracks above.

• Melatonin, Palbociclib, and Cyclin D1 — a separate preclinical ER-positive combination question tied to CDK4/6 biology
• DIY Liposomal Melatonin — formulation, storage, cost, and delivery context for readers exploring higher-exposure oral strategies

At a glance

• Best-supported human adjunct range: moderate nightly oral dosing, not chronic oral mega-dosing
• Main high-dose claim status: based mainly on cell and animal work, with human scaling still extrapolated
• Main caution: a transient RET-style pulse is not the same as taking very high oral doses every day
• Main human oral evidence: Lissoni trials and the Mills meta-analysis, not the RET studies

How to use the hub well

Keep the main separation clear.

• Do not treat the moderate adjunct discussion as the same as the RET-style high-dose discussion.
• Do not treat the condensate model as dose proof by itself.
• Use the dose-scaling and addendum pages whenever a dosing claim starts to outrun the actual evidence.